Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder
ConditionAlcohol Use Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorCentre for Addiction and Mental Health
About this trial
This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.
Eligibility criteria
Qualifiers
Meets DSM-5 criteria for AUD.
Meets drinking criteria of average weekly consumption > 10 standard drinks for women and > 15 standard drinks for men over the past 90 days.
Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol
Agrees not to use cannabis or illicit drugs during the study period.
Disqualifiers
Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment
History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens
Any history of seizures
Serious unstable medical condition, including severe hepatic abnormalities
Trial design
Treatments tested in this trial
- Oral solution
Treatment groups
36 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov